Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643902 | 0.79 | ADORA2A (0.38) | DCPSADORA2APIK3CDPIK3CANUDT1 | |
| SCHEMBL14213485 | 0.79 | HSD17B10 (0.50) | DCPSADORA2APIK3CDPIK3CANUDT1 | |
| SCHEMBL29569254 | 0.79 | HTT (0.41) | PIK3CDPIK3CAALDH1A1HPGD | |
| SCHEMBL1709918 | 0.79 | HTT (0.41) | PIK3CDPIK3CAALDH1A1HPGD | |
| SCHEMBL18305792 | 0.75 | DHFR (0.41) | DCPSDHFR | |
| SCHEMBL1789394 | 0.70 | PI4KA (0.42) | ADORA2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL1290607 | 0.69 | PIK3CD (0.30) | PIK3CDPIK3CA | |
| SCHEMBL3776231 | 0.69 | PDE4A (0.32) | — | |
| SCHEMBL16836336 | 0.68 | TLR8 (0.46) | DCPSADORA2ANUDT1ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL30791008 | 0.68 | PI4KA (0.41) | ADORA2AALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017205762-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | PHARMACYCLICS LLC (US) | 2017-11-30 | — | — | WO | claimed |
| US-20080261823-A1 | Fluorescent Nucleoside Analogs That Mimic Naturally Occurring Nucleosides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-10-23 | — | — | US | claimed |
| WO-2017205762-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | PHARMACYCLICS LLC (US) | 2017-11-30 | — | — | WO | disclosed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20080261823-A1 | Fluorescent Nucleoside Analogs That Mimic Naturally Occurring Nucleosides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | DCPS 1770/4885ADORA2A 441/4885PIK3CD 492/4885 |
| US-20080261823-A1 | Fluorescent Nucleoside Analogs That Mimic Naturally Occurring Nucleosides | NSUN2, NSUN3, NCL | DCPS 443/4885ADORA2A 243/4885PIK3CD 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.